Background {#Sec1}
==========

Epithelioid sarcoma (EpiS) is a rare soft tissue sarcoma that affects young adults and is characterized by a tendency toward local recurrence and metastasis \[[@CR1]\]. EpiS is classified into two subtypes according the clinicopathological features: a distal form that often arises in the distal extremities as a slow-growing nodule, and a proximal form that tends to arise in deeper areas of the pelvis, perineum and genital tract. Although the clinical course of proximal type may be more aggressive than that of distal type \[[@CR2], [@CR3]\], the clinical course is diverse, even for the same subtypes.

Although the molecular pathogenesis of EpiS remains unknown, deletion of the SMARCB1/INI1 tumor-suppressor gene (INI1) was recently reported in cases of proximal-type EpiS \[[@CR4]\] and subsequently in cases of distal-type EpiS \[[@CR5]\]. Loss of the INI1 expression is observed in approximately 80--90 % of distal and proximal EpiS patients \[[@CR6], [@CR7]\], and INI1 genetic inactivation is considered to be responsible for tumorigenesis in cases of EpiS \[[@CR8]\]. However, molecular biological aspects related to the progression of EpiS remain unclear, in addition to that associated with INI1, and few functional studies have focused on specific pathways in EpiS cases.

With respect to gaining further insight into the biology of sarcoma, proteomics studies are a powerful approach. Our previous proteomic study demonstrated the CAPZB expression in the tumor tissues of EpiS \[[@CR9]\]. In addition, CAPZB is known to increase actin filament depolymerization and capping, which promotes cell motility \[[@CR10], [@CR11]\], although functions other than cell motility have not been reported so far. According to the Human Protein Atlas (<http://www.proteinatlas.org>), CAPZB is also expressed in normal tissue (lymphoid cells, seminiferous ducts, urothelium and placenta exhibited strong staining) and also in certain types of tumors (lymphoma and testicular cancer). In addition, several previous proteomic studies have identified the differential expression of CAPZB \[[@CR12], [@CR13]\]. However, the functional roles and clinical impacts of CAPZB expression in these tumors are unknown. Several previous studies have briefly described the functions of CAPZB \[[@CR11], [@CR14], [@CR15]\], focusing on its role as a capping protein (CP). CPs are important for the dynamics of actin filament assembly and regulation of the cell shape and movement in vitro \[[@CR16]--[@CR19]\]. However, the functions of CAPZB in EpiS have not yet been elucidated.

In the current study, in order to elucidate the functions of CAPZB in EpiS, we performed functional assays using gene silencing of CAPZB in EpiS cell lines. Consequently, a proteomics study followed by a pathway analysis revealed the SWI/SNF chromatin remodeling complex, which includes INI1, as a possible upstream regulator of CAPZB in the setting of EpiS. We herein describe the oncogenic functions of CAPZB in EpiS, with emphasis on the association with INI1.

Methods {#Sec2}
=======

Immunohistochemistry {#Sec3}
--------------------

Fifteen cases of EpiS (distal type: 9 cases, proximal type: 6 cases) were chosen from among the pathological records at Juntendo University Hospital or the National cancer Center, Japan According to the World Health Organization (WHO) Classification of Tumors \[[@CR20]\], the pathological diagnosis of EpiS for each FFPE case were made by an experienced sarcoma-based pathologist with the conventional immunohistochemical staining such as cytokeratin, EMA, CD34 and vimentin. All cases were positive for CD34, and also positive for at least either cytokeratin or EMA. Loss of INI1 expression was also confirmed for all cases. These fifteen cases of EpiS were used for immunohistochemistry for CAPZB. In brief, 4-μm-thick tissue sections were cut from formalin-fixed, paraffin-embedded blocks. Following deparaffinization, the sections were autoclaved for antigen retrieval in Tris-EDTA buffer (pH 9.0) at 121 °C for 30 min and incubated with a commercial monoclonal antibody against CAPZB (dilution 1: 200, Abcam, ab122980). Immunostaining was carried out according to the streptavidin biotin peroxidase method using a Strept ABC Complex/horseradish peroxidase kit (DAKO, Glostrup, Denmark). Because it has been shown that CAPZB generally localize at the cytoplasm or cellular membrane, we counted only cytoplasmic/membranous staining as positive staining. We uploaded files of the CAPZB immunohistochemical staining of all cases as Additional file [1](#MOESM1){ref-type="media"}: Figure S1 and Additional file [2](#MOESM2){ref-type="media"}: Figure S2.

Regarding the positive and negative controls of CAPZB IHC, lymphoid cells served as positive control and smooth muscle cells of the vessels as negative control in the immunohistochemical sections, as shown in the Human Protein Atlas homepage (<http://www.proteinatlas.org/>). Lymphoid cells served as positive control and smooth muscle cells as negative control.

This study was approved by the ethical review board of Juntendo University Hospital and the National Cancer Center, and signed informed consent was obtained from all of the study patients.

Cell lines {#Sec4}
----------

Two EpiS cell lines, VAESBJ (CRL-2138, American Type Culture Collection) and ESX (kindly provided by Sapporo Medical College, Sapporo, Japan) were used in this study. The cells were maintained in DMEM (Life Technologies, Inc., Bethesda, MD) and IMDM (Life Technologies, Inc., Bethesda, MD) supplemented with 10 % FBS, respectively. The cells were incubated at 37 °C in 5 % CO~2~. VAESBJ cells have a deletion of the INI1 gene \[[@CR8]\] and show the loss of the INI1 protein expression, whereas ESX cells exhibit the INI1 protein expression \[[@CR21]\].

Knockdown of CAPZB in EpiS cell lines {#Sec5}
-------------------------------------

The EpiS cell lines were treated with 20 nM of two siRNAs for CAPZB (Hs_CAPZB_5777 and Hs_CAPZB_5779, Sigma-Aldrich, St. Louis, MO, USA), siRNA1 (5′ --CUCGUUAGAUUCCUUUCUUTT--3′, antisense 5′ --AAGAAAGGAAUCUAACGAGTT--3′) and siRNA2 (sense 5′ --GGGAUUCCAUCCACGUGGUTT--3′, antisense 5′ --ACCACGUGGAU--GGAAUCCCTT-3′), or siRNA negative control (Sigma-Aldrich, St. Louis, MO, USA) using Lipofectamine™ RNAiMAX reagent (Invitrogen, Carlsbad, CA, USA). At 72 h after transfection, total protein was isolated from each cell line, and the expression level of CAPZB was validated using a Western blotting analysis.

Western blotting {#Sec6}
----------------

The proteins were separated via SDS-PAGE and transferred to nitrocellulose membranes. The membranes were incubated with either of the following antibodies: mouse monoclonal antibodies against CAPZB (dilution 1: 1,000, Abcam, ab122980), INI1 (dilution 1: 500, BD Transduction Laboratories, 612110) or GAPDH (dilution 1: 500, Santa Cruz, sc-32233). After incubation, the membranes were washed three times with Tris-EDTA buffer and then reacted with horseradish peroxidase-conjugated secondary antibodies (1:1,000 dilution, GE Healthcare Biosciences).

Preparation of retrovirus and transduction of the cell lines {#Sec7}
------------------------------------------------------------

The Tet-On expression system was used for transduction of the genes of interest, and the TRMPV-Neo (Addgene Plasmid \#27990) vector system was used for retrovirus production (PMID: 21131983). The sh-RNA site was deleted from the TRMPV-Neo vector for the DsRed overexpression vector (TRMPV-DsRed-Neo), and SMARCB1 was subcloned from human diploid fibroblasts into the position of DsRed for TRMPV-SMARCB1-Neo. MSCV-rtTA-EcoR-Puro was kindly provided by Dr. Scott Lowe. Retroviruses were obtained using 293 T cells as packaging cells, infected into the EpiS lines and selected with 4 μg/ml of puromycin or 500 μg/ml of G418 (Invitrogen, Carlsbad, CA, USA). Transcription of the TRE-regulated target gene was stimulated by rtTA in the presence of 10 ng/ml of doxycycline (Dox) (Sigma-Aldrich, St. Louis, MO, USA).

Cell proliferation assay {#Sec8}
------------------------

VAESBJ and ESX cells were seeded in 96-well plates at 2,000 cells/well and 3,000 cells/well, respectively on day 1. On day 1, transfection was performed with 20 nM of the same siRNA reagents described above. Cell proliferation was monitored using the Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) and a microplate reader to measure the absorbance of the culture medium at 450 nm according to the manufacturer's instruction manual. All proliferation experiments were performed in triplicate, and the results were averaged.

Invasion assay {#Sec9}
--------------

The invasion assays were performed using 24-well BD BioCoat Matrigel Invasion Chambers (BD Biosciences, Franklin Lakes, NY), according to the manufacturer's protocol. VAESBJ and ESX cell suspensions were prepared at a density of 8 × 10^4^ cells/mL and 3 × 10^5^ cells/mL in 0.5-ml serum-free medium and added to the gel chamber insert. After 48 h of incubation, non-invading cells were removed with cotton swabs, and invading cells were stained using Diff-Quick reagent (Sysmex, Kobe, Hyogo, Japan). The number of invading cells was counted, and the invasion index was calculated as the percent invasion of transfected cells/non-transfected cells.

Scratch assay {#Sec10}
-------------

The rate of cell migration was assessed using a scratch assay. The VAESBJ cell line transfected with CAPZB siRNA was seeded on a 6-well plate and allowed to reach confluence. After scratching the bottom of the well with a pipette tip, the monolayer of cells was washed with PBS to remove detached cells. The remaining adherent cells were incubated in medium containing 0.2 % FBS, and the area of the scratch wound was evaluated at 48 h after transfection. The experiments were performed in triplicate.

Proteomic analysis using iTRAQ (isobaric tags for relative and absolute quantification) and mass spectrometry {#Sec11}
-------------------------------------------------------------------------------------------------------------

Isobaric tags for relative and absolute quantification (iTRAQ), a form of chemical labeling mass spectrometry, were created according to the company's protocol \[[@CR22]\]. Briefly, the cell lysate was extracted from each cell and subjected to a LC-shot gun analysis using the iTRAQ method, as previously described \[[@CR23]\]. Prior to the iTRAQ analysis, the lysate samples were concentrated and buffer exchanged using a 3.5-kDa molecular weight cut-off spin concentrator (TOMY SEIKO CO., LTD, Tokyo, Japan) then digested for 24 h with 10 μg of L-1-(4-tosylamido)-2-phenylethyl tosyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin. Each peptide solution was labelled with one of the four iTRAQ reagents (iTRAQ reporter ions of 114, 115, 116 and 117 mass/charge ratio) according to the manufacturer's protocol (AB SCIEX, Framingham, MA, USA). The labelled peptides were pooled and fractionated via strong cation exchange (SCX) using a ChromXP C18-CL column (Eksigent parts of AB SCIEX, Dublin, California, USA) and analyzed with nano LC-MS/MS \[[@CR24]\]; nano LC-MS/MS was performed using a TripleTOF® 5600 mass spectrometer for MS/MS (AB SCIEX) interfaced with a nano LC system (Eksigent parts of AB SCIEX).

Peptide identification {#Sec12}
----------------------

Protein identification and relative quantification were carried out as previously described (ProteinPilot™ Software Version 4.5) \[[@CR25]\]. Functional definitions of the variable protein contents were searched against the Swissport database (Release, 6/20/2014) using the search algorithm contained within the ProteinPilot™ Software and Analyst® TF Software programs (AB SCIEX). The protein ratios were normalized using the overall median ratio for all peptides in the sample for the separate ratios in each individual experiment. A confidence cutoff value for protein identification of \>95 % was applied for protein identification, and a \>1.2-fold change cutoff was selected for all of the iTRAQ ratios in order to classify proteins as upregulated or downregulated as previously described \[[@CR26]\].

Pathway analysis {#Sec13}
----------------

The Ingenuity Pathways Analysis (IPA) (Ingenuity Systems, Redwood City, CA) software program was further used to determine the functional pathways represented by the identified genes. The IPA software package contains a database of biological interactions among genes and proteins, which was used to calculate the probability of a relationship between each canonical pathway, upstream pathway and the identified proteins. The IPA program scans the set of input proteins to identify networks using the Ingenuity Pathway Knowledge Base (IPKB) for interactions between identified proteins and known and hypothetical interacting genes stored in the IPA software database.

Statistical Analysis {#Sec14}
--------------------

Data from the western blotting and quantitative-PCR were analyzed using the t-test. The significance of differences in the functional assays of EpiS cell lines following transfection was evaluated using the t-test.

The statistical analysis of protein expression profiles is based on *p*-value and threshold using Protein Pilot version 4.5 software (AB SCIEX) \[[@CR27]\].

Results {#Sec15}
=======

CAPZB expression in EpiS clinical samples and EpiS cells {#Sec16}
--------------------------------------------------------

Fifteen cases of EpiS were examined using immunohistochemistry to confirm the protein expression and localization of CAPZB. In all 15 cases, more than 70 \~ 80 % of tumor cells were positive for CAPZB and CAPZB was localized in the cytoplasm. Some cases also showed nuclear staining (Fig. [1a](#Fig1){ref-type="fig"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S1 and Additional file [2](#MOESM2){ref-type="media"}: Figure S2). These results were consistent with the findings of our previous proteomic analysis showing that tumor tissues of ES have higher CAPZB expression levels than normal tissues \[[@CR9]\]. In the present study, we also confirmed the expressions of CAPZB in the two EpiS cell lines (VAESBJ and ESX cells) using WB (Fig. [1b](#Fig1){ref-type="fig"}).Fig. 1Localization and expression of CAPZB in EpiS. **a** Immunohistochemistry in representative EpiS case shows the CAPZB expression in the tumor cells. **b** CAPZB is strongly expressed in the two EpiS cell lines. Treatment with the two siRNAs (si-CAPZB-1 and si-CAPZB-2) significantly decreases the expression levels of CAPZB in the two cell lines

Functional analysis of CAPZB {#Sec17}
----------------------------

In order to investigate the cellular functions of CAPZB in EpiS, we performed siRNA assays of CAPZB using the two EpiS cell lines. As a result, treatment with two siRNAs (si-CAPZB-1 and si-CAPZB-2) significantly decreased the expression levels of CAPZB compared to that observed in the control cells for both the VAESBJ and ESX cells (Fig. [1b](#Fig1){ref-type="fig"}). Following gene silencing of CAPZB by the two siRNAs in both EpiS cell lines, we performed in vitro assays consisting of cell proliferation, invasion and scratch assays. In the cell proliferation assays, knockdown of CAPZB significantly decreased the rate of cell growth at 96 h after transfection in both the VAESBJ and ESX cells (Fig. [2a](#Fig2){ref-type="fig"}). In the invasion assays, the CAPZB-silenced cells demonstrated markedly decreased cell invasion (Fig. [2b](#Fig2){ref-type="fig"}). In the scratch assays, silencing of CAPZB in the VAESBJ cells significantly suppressed cell migration compared to that observed in the control cells (Fig. [2c](#Fig2){ref-type="fig"}). We were unable to obtain cell migration data for the ESX cells because these cells easily detached from the culture plate with scratching.Fig. 2Progressive effect of CAPZB in EpiS cellular function. **a** In the proliferation assays, si-CAPZB-1 and si-CAPZB-2 inhibited cell growth by 85 % and 81 % in the VAESBJ cells and 71 % and 65 % in the ESX cells, respectively (*p* \< 0.01, *p* \< 0.05, Figure 2B left and right, respectively). **b** In the invasion assays, si-CAPZB-1 and si-CAPZB-2 decreased cell invasion by 63 % and 48 % in the VAESBJ cells and 57 % and 56 % in the ESX cells, respectively (*p* \< 0.01, *p* \< 0.05, Figure 2c left and right, respectively). **c** In the scratch assays, CAPZB silencing suppressed the area of wound healing in the VAESBJ cells (*p* \< 0.01, Control: 32 %, si-CAPZB-1: 21 %, si-CAPZB-2: 22 %, Fig. 2d)

Next, we performed a proteomics approach using i-TRAQ assays with the CAPZB siRNA-transfected EpiS cells in order to determine the differences in the protein expression profile according to the knockdown of CAPZB in EpiS. Consequently, the protein expression profiles differed significantly between the CAPZB-silenced cells and the control cells (*p* \< 0.05). This analysis revealed protein profiles consisting of 26 downregulated proteins and 39 upregulated proteins in the VAESBJ cells (*p* \< 0.05, Table [1](#Tab1){ref-type="table"}), as well as 69 downregulated proteins and 41 upregulated proteins in the ESX cells (*p* \< 0.05, Table [2](#Tab2){ref-type="table"}). The numbers of commonly upregulated and downregulated proteins between two cell lines were 3 and 8, respectively. In order to further understand the biological networks associated with CAPZB, we employed a network analysis using the IPA system with the above obtained protein profiles in the VAESBJ and ESX cells. The results of the IPA analyses are shown in Additional file [1](#MOESM1){ref-type="media"}: Figure S1, Additional file [2](#MOESM2){ref-type="media"}: Figure S2, Additional file [3](#MOESM3){ref-type="media"}: Table S1 and Additional file [4](#MOESM4){ref-type="media"}: Table S2. These results pointed to several SWI/SNF chromatin-remodeling complexes as possible upstream regulators or critical pathways among the identified network lists. We also found INI1 to be included in the identified SWI/SNF chromatin-remodeling complex list (Additional file [3](#MOESM3){ref-type="media"}: Table S1 and Additional file [4](#MOESM4){ref-type="media"}: Table S2).Table 1Protein profiles of CAPZB-regulated proteins in the VAESBJ cells^a^Accession no.SymbolProtein nameFold difference*P* valueP07355ANXA2Annexin A21.900.00E+00P02768ALBUSerum albumin1.852.17E-02P081954 F2Isoform 3 of 4 F2 cell-surface antigen heavy chain1.631.00E-04Q16222UAP1UDP-N-acetylhexosamine pyrophosphorylase1.553.10E-03Q09666AHNKNeuroblast differentiation-associated protein AHNAK1.530.00E+00P08243ASNSAsparagine synthetase \[glutamine-hydrolyzing\]1.452.00E-04Q96HC4PDLI5PDZ and LIM domain protein 51.441.37E-02P13797PLSTPlastin-31.440.00E+00P215895NTD5′-nucleotidase1.435.10E-03P15144AMPNAminopeptidase N1.421.00E-03P26639SYTCThreonine---tRNA ligase, cytoplasmic1.392.00E-04Q05682CALD1Isoform 5 of Caldesmon1.383.20E-03P06756ITAVIntegrin alpha-V1.332.14E-02P21333FLNAIsoform 2 of Filamin-A1.320.00E+00P05556ITB1Integrin beta-11.320.00E+00P18206VINCVinculin1.310.00E+00P06737PYGLGlycogen phosphorylase, liver form1.301.13E-02O43175SERAD-3-phosphoglycerate dehydrogenase1.301.27E-02P00390GSHRGlutathione reductase, mitochondrial1.293.08E-02P16989YB0X3Y-box-binding protein 31.293.19E-02Q9UKK3PARP4Poly \[ADP-ribose\] polymerase 41.294.22E-02Q9Y617SERCPhosphoserine aminotransferase1.281.80E-02P06733ENOAAlpha-enolase1.261.00E-03P00352AL1A1Retinal dehydrogenase 11.261.00E-04P49591SYSCSerine---tRNA ligase, cytoplasmic1.249.70E-03P20810ICALIsoform 9 of Calpastatin1.232.19E-02P41250SYGGlycine---tRNA ligase1.232.51 E-02O60884DNJA2DnaJ homolog subfamily A member 21.212.44E-02Q9NSE4SYIMIsoleucine---tRNA ligase, mitochondrial1.212.46E-02P61289PSME3Proteasome activator complex subunit 31.211.26E-02P27824CALXCalnexin1.201.24E-02P15311EZRIEzrin1.202.00E-04Q9BXJ9NAA15N-alpha-acetyltransferase 15, NatA auxiliary subunit1.193.35E-02P43490NAMPTNicotinamide phosphoribosyltransferase1.181.59E-02Q01813K6PP6-phosphofructokinase type C1.182.47E-02O75369FLNBIsoform 2 of Filamin-B1.166.00E-04P22102PUR2Trifunctional purine biosynthetic protein adenosine-31.155.80E-03P49411EFTUElongation factor Tu, mitochondrial1.101.77E-02P38646GRP75Stress-70 protein, mitochondrial1.104.13E-02Q00610CLH1Clathrin heavy chain 10.914.92E-02P13010XRCC5X-ray repair cross-complementing protein 50.902.90E-02P25685DNJB1DnaJ homolog subfamily B member 10.851.49E-02P619811433G14-3-3 protein gamma0.852.42E-02P30086PEBP1Phosphatidylethanolamine-binding protein 10.841.79E-02P09382LEG1Galectin-10.843.48E-02P08133ANXA6Annexin A60.842.00E-04043747AP1G1Isoform 2 of AP-1 complex subunit gamma-10.832.44E-02P05787K2C8Keratin, type II cytoskeletal 80.824.00E-04P10644KAPOcAMP-dependent protein kinase type I-alpha regulatory subunit0.814.19E-02Q9NZ01TECRVery-long-chain enoyl-CoA reductase0.814.10E-02Q9BUJ2HNRL1Heterogeneous nuclear ribonucleoprotein U-like protein 10.813.70E-02O14579COPECoatomer subunit epsilon0.804.18E-02P08727K1C19Keratin, type I cytoskeletal 190.794.10E-03P07108ACBPIsoform 3 of Acyl-CoA-binding protein0.792.54E-02P631041433Z14-3-3 protein zeta/delta0.781.61 E-02Q15274NADCNicotinate-nucleotide pyrophosphorylase \[carboxylating\]0.784.40E-02P25705ATPAATP synthase subunit alpha, mitochondrial0.771.82E-02P04080CYTBCystatin-B0.771.03E-02P53634CATCDipeptidyl peptidase 10.773.85E-02Q07955SRSF1Serine/arginine-rich splicing factor 10.761.99E-02Q9NQC3RTN4Isoform 2 of Reticulon-40.712.76E-02P00568KAD1Adenylate kinase isoenzyme 10.705.10E-03Q7L1QBBZW1Basic leucine zipper and W2 domain-containing protein 10.651.10E-03Q9ULV4COR1CIsoform 3 of Coronin-1C0.632.10E-03P52907CAZA1F-actin-capping protein subunit alpha-10.621.71E-02P04264K2C1Keratin, type II cytoskeletal 10.392.00E-04P04179SODMSuperoxide dismutase \[Mn\], mitochondrial0.343.08E-02P35527K1C9Keratin, type I cytoskeletal 90.294.20E-03^a^Accession numbers of proteins were derived from Swiss-Plot data baseTable 2Protein profiles of CAPZB-regulated proteins in the ESX cells^a^Accession no.SymbolNameFold difference*P* valueQ15738NSDHLSterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating2.022.50E-03Q9P287BCCIPBRCA2 and CDKN1 A-interacting protein2.023.48E-02Q9NZL4HPBP1Hsp70-binding protein 11.902.65E-02P14174MIFMacrophage migration inhibitory factor1.843.30E-02P20591MX1Interferon-induced GTP-binding protein Mx11.822.64E-02P20936RASA1Ras GTPase-activating protein 11.764.03E-02O95373IP07Importin-71.737.70E-03P27144KAD4Adenylate kinase 4, mitochondrial1.671.44E-02Q96EK5KBPKIF1---binding protein1.651.70E-02Q9P2J5SYLCLeucine---tRNA ligase, cytoplasmic1.641.17E-02P49354FNTAProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha1.637.40E-03P25786PSA1Proteasome subunit alpha type-11.583.89E-02P49773HINT1Histidine triad nucleotide-binding protein 11.527.20E-03P51003PAPOAPoly(A) polymerase alpha1.512.49E-02P09211GSTP1Glutathione S-transferase P1.504.95E-02P07339CATDCathepsin D1.502.52E-02P12277KCRBCreatine kinase B-type1.464.14E-02P61289PSME3Proteasome activator complex subunit 31.444.77E-02Q4J6C6PPCELProlyl endopeptidase-like1.434.89E-02Q6IBS0TWF2Twinfilin-21.434.96E-02P14625ENPLEndoplasmin1.420.00E+00P55060XP02Exportin-21.421.30E-03P08238HS90BHeat shock protein HSP 90-beta1.394.10E-02P30041PRDX6Peroxiredoxin-61.381.02E-02O00410IP05Isoform 3 of Importin-51.372.24E-02Q14697GANABNeutral alpha-glucosidase AB1.362.03E-02P13797PLSTPlastin-31.365.50E-03043681ASNAATPase ASNA11.323.37E-02P27824CALXCalnexin1.313.94E-02P48735IDHPIsocitrate dehydrogenase \[NADP\], mitochondrial1.304.29E-02P50395GDIBRab GDP dissociation inhibitor beta1.302.38E-02O60488ACSL4Long-chain-fatty-acid---CoA ligase 41.291.79E-02P80303NUCB2Nucleobindin-21.292.91 E-02P05455LALupus La protein1.272.40E-02Q15084PDIA6Protein disulfide-isomerase A61.264.60E-03Q16576RBBP7Histone-binding protein RBBP71.254.35E-02Q99832TCPHT-complex protein 1 subunit eta1.244.78E-02P50990TCPQT-complex protein 1 subunit theta1.219.70E-03P10809CH6060 kDa heat shock protein, mitochondrial1.184.64E-02Q06830PRDX1Peroxiredoxin-11.182.23E-02P50502F10A1Hsc70-interacting protein1.151.39E-02O75369FLNBIsoform 2 of Filamin-B0.851.33E-02P12814ACTN1Isoform 3 of Alpha-actinin-10.843.51 E-02P35580MYH10Myosin-100.841.10E-03P09496CLCAClathrin light chain A0.844.71 E-02P21333FLNAIsoform 2 of Filamin-A0.845.00E-04P26583HMGB2High mobility group protein B20.831.86E-02O60841IF2PEukaryotic translation initiation factor 5B0.833.66E-02Q08257QORQuinone oxidoreductase0.832.95E-02Q9Y3A5SBDSRibosome maturation protein SBDS0.824.20E-02Q14203DCTN1Dynactin subunit 10.814.67E-02Q00839HNRPUHeterogeneous nuclear ribonucleoprotein U0.812.61 E-02O15371EIF3DEukaryotic translation initiation factor 3 subunit D0.794.68E-02Q6UB35C1TMMonofunctional C1\~tetrahydrofolate synthase, mitochondrial0.793.39E-02P39019RS1940S ribosomal protein S190.771.28E-02P27816MAP4Isoform 6 of Microtubule-associated protein 40.774.66E-02Q00688FKBP3Peptidyl-prolyl cis-trans isomerase FKBP30.773.16E-02Q9BUJ2HNRL1Heterogeneous nuclear ribonucleoprotein U---like protein 10.761.06E-02P081954 F2Isoform 3 of 4 F2 cell-surface antigen heavy chain0.762.10E-02P52272HNRPMHeterogeneous nuclear ribonucleoprotein M0.702.82E-02Q15274NADCNicotinate-nucleotide pyrophosphorylase \[carboxylating\]0.763.26E-02Q12906ILF3Interleukin enhancer-binding factor 30.702.04E-02P08670VIMEVimentin0.751.00E-04P18124RL70OS ribosomal protein L70.741.15E-02Q92841DDX17Isoform 4 of Probable ATP-dependent RNA helicase DDX170.745.60E-03P62906RL10A80S ribosomal protein L10a0.732.09E-02P16989YBOX3Y-box-binding protein 30.731.50E-02P05161ISG15Ubiquitin---like protein ISG150.732.87E-02P06748NPMNucleophosmin0.721.07E-02O00571DDX3XATP-dependent RNA helicase DDX3X0.717.00E-03P62424RL7A80S ribosomal protein L7a0.713.87E-02P46776RL27A60S ribosomal protein L27a0.713.40E-02P83881RL30A60S ribosomal protein L36a0.702.03E-02P46777RL560S ribosomal protein L50.702.00E-04P62913RL1160S ribosomal protein L110.701.04E-02P50914RL1460S ribosomal protein L140.702.61 E-02P62280RS1140S ribosomal protein S110.701.18E-02P62917RL860S ribosomal protein L80.705.00E-03P84098RL1960S ribosomal protein L190.691.27E-02P62241RS840S ribosomal protein S80.692.37E-02P6322ORS2140S ribosomal protein S210.691.24E-02Q05682CALD1Isoform 5 of Caldesmon0.691.00E-04P54886P5CSDelta-1 -pyrroline-5-carboxylate synthase0.681.10E-03P01247RS3A40S ribosomal protein S3a0.687.00E-04P35613BASIIsoform 2 of Basigin0.682.83E-02P26373RL1360S ribosomal protein L130.682.19E-02Q14789GOGB1Golgin subfamily B member 10.672.56E-02P05023AT1A1Sodium/potassium-transporting ATPase subunit alpha-10.672.00E-04P52907CAZA1F-actin-capping protein subunit alpha-10.662.86E-02P09382LEG1Galectin-10.661.40E-02P09874PARP1Poly \[ADP-ribose\] polymerase 10.662.00E-04P6275ORL23A60S ribosomal protein L23a0.664.00E-04Q8NC51PAIRBPlasminogen activator inhibitor 1 RNA-binding protein0.651.00E-04P46779RL2860S ribosomal protein L280.651.13E-02P49748ACADVVery long-chain specific acyl-CoA dehydrogenase, mitochondrial0.651.74E-02Q01082SPTB2Spectrin beta chain, non-erythrocytic 10.640.00E+00Q07955SRSF1Serine/arginine-rich splicing factor 10.643.94E-02Q9NZI8IF2B1Insulin-like growth factor 2 mRNA-binding protein 10.634.10E-03Q02878RL660S ribosomal protein L60.622.90E-03Q15233NONONon-POU domain-containing octamer-binding protein0.622.64E-02P07910HNRPCHeterogeneous nuclear ribonucleoproteins C1/C20.610.00E+00P08133ANXA6Annexin A60.600.00E+00Q07020RL1860S ribosomal protein L180.601.00E-02Q7L1Q6BZW1Basic leucine zipper and W2 domain-containing protein 10.591.00E-04Q16643DREBDrebrin0.581.00E-04Q9ULV4COR1CIsoform 3 of Coronin-1C0.576.30E-03P47756CAPZBIsoform 2 of F-actin-capping protein subunit beta0.553.01 E-02043707ACTN4Alpha-actinin-40.540.00E+00P16070CD44Isoform 11 of CD44 antigen0.543.10E-03P22626ROA2Heterogeneous nuclear ribonucleoproteins A2/B10.522.12E-02^a^Accession numbers of proteins were derived from Swiss-Plot data base

In order to elucidate the possible association between the INI1 and CAPZB expression, we performed siRNA assays of CAPZB in the two EpiS cell lines and measured the expression levels of CAPZB and INI1 using WB. In the ESX cell line (without the loss of INI1), gene silencing of CAPZB led to a decrease in the expression level of INI1 (Fig. [3](#Fig3){ref-type="fig"}, right). In the VAESBJ cell line (with the loss of INI1), the INI1 expression remained lost (Fig. [3](#Fig3){ref-type="fig"}, left).Fig. 3Association between the expression of CAPZB and INI1 in EpiS cells. In the ESX cells, suppression of the CAPZB expression inhibited the expression of INI1 in both siRNA assays. We were unable to evaluate the association between CAPZB and INI1 in the VAESBJ cells, because this cell line had deletions of INI1 and did not show an expression of INI1

Next, we attempted to assess the effects of INI1 overexpression in the VAESBJ and ESX cells. These EpiS cell lines were stably transfected with either Dox-inducible empty (RFP) or the INI1 expression vector, and the expression levels of INI1 were confirmed with WB. In the VAESBJ cell line, in which INI1 was lost, Dox induction in the INI1-transfected cells (INI1+) induced the INI1 expression (Fig. [4a](#Fig4){ref-type="fig"}, upper left). In the ESX cell line, Dox induction in the INI1-transfected ESX cells resulted in a higher expression of INI1 than that noted in the other three cell lines (Fig. [4a](#Fig4){ref-type="fig"}, upper right). According to the presence of INI1 induction, a real-time PCR assay revealed that the expression level of CAPZB in the Dox-induced INI1-transfected cells was significantly higher than that observed in the other three cells among the VAESBJ cells (Fig. [4c](#Fig4){ref-type="fig"}). However, the WB assay did not detect apparent differences in the CAPZB expression (Fig. [4a](#Fig4){ref-type="fig"}, middle). Based on these findings, it was difficult to assume the direct effect of INI1 on CAPZB in EpiS cells. Regarding the proliferation of the Dox-induced INI1-overexpressing cells, the cell growth of the Dox-induced INI1-overexpressing VAESBJ cells was markedly suppressed compared to that of the control cells (Fig. [4b](#Fig4){ref-type="fig"}, left). However, the Dox-induced INI1-overexpression in VAESBJ cells did not affect the migration and invasion properties (Data not shown). In contrast, in the ESX cell lines, Dox-induced INI1-overexpression did not affect cell proliferation (Fig. [4b](#Fig4){ref-type="fig"}, right).Fig. 4The expression levels of CAPZB and cell growth in INI1-overexpressing EpiS cells. **a** In the VAESBJ cell line, the INI1 expression was induced in the doxycycline (Dox)-induced INI1-overexpressing cells, whereas the other three cells did not show an expression of INI1 (**a**, left panel). In the ESX cell line, all four cells expressed INI1, and the Dox-induced INI1-overexpressing cells had higher expression levels than the other three cells (**a**, right panel). Regarding the expression levels of CAPZB, the WB assay demonstrated no remarkable differences among the four types of cells for both the VAESBJ and ESX cells. **b** In the cell proliferation assay, a significant growth inhibition was observed in the Dox-induced INI1-overexpressing cells (*p* \< 0.01, B, left panel). The cell proliferation assays of the ESX cells showed no significant differences in growth between the INI1-overexpressing cells and the control cells (**b**, right panel). **c** Relative expression of CAPZB mRNA in the VAESBJ and ESX cells (right and left panel, respectively). The mean expression levels of CAPZB in the RFP DOX-, RFP DOX+, INI1 Dox- and INI1 Dox + cells of each cell line, as determined using real-time PCR are shown, normalized to the expression of CAPZB mRNA in the RFP DOX- cells. In the VAESBJ cells, the INI1 Dox + cells had higher mRNA expression levels of CAPZB than the other three cells (**c**, left panel). On the other hand, in the ESX cells, there were no significant differences in the mRNA expression levels of CAPZB among the four cells (**c**, right panel)

Discussion {#Sec18}
==========

Capping proteins are known to increase actin filament depolymerization and promote cell motility \[[@CR10], [@CR11]\]. However, the associations between the expression levels of capping proteins, including CAPZB, and cancer phenotypes remain unknown. Furthermore, although we have previously reported high CAPZB expression in the tumor tissues of EpiS \[[@CR9]\], relative expression of CAPZB in EpiS compared to other types of tumors is unknown, therefore it is difficult to refer to the association between the relative expression level of CAPZB and aggressive behavior of the tumors. Recently, CAPZA1, a member of the capping protein family, was reported to have prognostic value and a suppressive effect on cell migration and invasion in gastric cancer tissue \[[@CR28]\], whereas the overexpression of actin-capping proteins has been shown to modulate cell motility in vitro, suggesting their potentially important role in promoting cell motility in the setting of pancreatic cancer \[[@CR29]\]. These findings indicate that members of the capping protein family, including CAPZB, contribute to tumor progression in several cancers in a tumor-specific manner. In the present study, we confirmed the CAPZB expression in EpiS clinical samples and cell lines and showed that CAPZB contributes to tumor progression in the setting of EpiS by promoting cellular proliferation, invasion and migration, thus demonstrating that CAPZB functions as an oncoprotein in the pathogenesis of EpiS.

It is also of interest to identify which biological pathways are involved in promoting the tumor progression induced by CAPZB in cases of EpiS. Therefore, we performed a proteomics study to examine changes in the protein expression profiles according to the knockdown of CAPZB. Protein profiles differentially expressed based on the knockdown of CAPZB included MX1 and BCCIP as upregulated proteins and CD44 and FLNB as downregulated proteins. Some of these proteins were identified as down stream regulator of SWI/SNF complexes including INI1 by using IPA analysis (Table S1 and S2). MX1, Interferon-induced GTP-binding protein MX1, was involved in antiviral responses \[[@CR30], [@CR31]\]. Previous proteomic study referred this protein as to be a marker of lymph node metastasis and having functional role of tumor invasion in colorectal carcinoma \[[@CR32]\]. BCCIP, protein which interacts with BRCA2 and CDKN1A, has been implicated in many cellular processes including cell cycle regulation, DNA recombination and damage repair \[[@CR33]\]. BCCIP suppresses the growth of certain tumor cells \[[@CR34]\], but is required for tumor progression \[[@CR35]\]. CD44 is a transmembranous glycoprotein which was involved in cell adhesion, cell migration, and metastasis \[[@CR36], [@CR37]\]. The BRG-1 subunit of the SWI/SNF complexes is a critical regulator of CD44 expression \[[@CR38]\]. FLNB is one of the three isoforms of filamins which were actin-binding cross linking proteins \[[@CR39]\]. FLNs were involved in initiation of cell migration \[[@CR40]\]. These protein profiles help to explain how CAPZB exerts its tumor-accelerating effects in EpiS tissues.

In addition, it is interesting to note that the network analyses performed after the proteomics study identified several SWI/SNF chromatin-remodeling complexes including INI1 as upstream regulators of CAPZB, although INI1 itself was not included in the differentially expressed protein list according to CAPZB knockdown. INI1 is a key member of the SWI/SNF complex, and SWI/SNF complexes play essential roles in a variety of cellular processes, including differentiation, proliferation and DNA repair. The loss of SWI/SNF subunits has been reported in a number of malignant rhabdoid cell lines and tumors, and a large number of experimental observations suggest that this complex functions as a tumor suppressor \[[@CR41]\]. In particular, loss of the INI1 protein expression has recently been reported in other tumors as well, including most cases of EpiS \[[@CR42]\]. These findings prompted us to investigate the possible relationship between CAPZB and INI1 in EpiS. Consequently, silencing of CAPZB definitively suppressed cell proliferation in the setting of EpiS, although, surprisingly, the expression levels of INI1, which possesses a tumor suppressor function, were decreased in the ESX cells. On the other hand, the induction of INI1 in the INI1-negative EpiS cells (VAESBJ cells) definitively suppressed cell growth. Furthermore, according to INI1 induction, the CAPZB mRNA expression levels increased significantly (Fig. [4c](#Fig4){ref-type="fig"}), although the changes in the protein expression levels were not detectable by WB assays. These results suggest that the relationship between INI1 and CAPZB is complex and involves several co-mediators. We believe that further functional studies may help to clarify the interactions and networks between CAPZB and INI1 and that our functional and global protein expression data provide novel information for conducting such studies.

Conclusions {#Sec19}
===========

In summary, we found that CAPZB contributes to the cell growth and motility of EpiS cells, irrespective of the INI1 expression, highlighting a possible role of CAPZB in metastasis and tumor development in cases of EpiS. Nevertheless, the paradoxical relationship between the tumor suppressor INI1 and the oncoprotein CAPZB in EpiS remains to be clarified.
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CAPZB

:   F-actin capping protein subunit beta

EpiS

:   Epithelioid sarcoma

i-TRAQ

:   Isobaric tags for relative and absolute quantitation

IPA

:   Ingenuity pathways analysis

SMARCB1

:   SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1

Cp

:   Capping protein

FFPE

:   Formalin-fixed, paraffin-embedded

IHC

:   Immunohistochemistry

LC-MS/MS

:   Liquid chromatography-tandem mass spectrometry

PCR

:   Polymerase chain reaction

CAPZA1

:   F-actin-capping protein subunit alpha-1

MX1

:   Interferon-induced GTP-binding protein MX1

BCCIP

:   BRCA2 and CDKN1A-interacting protein

SWI/SNF

:   Switch/sucrose non-fermentable
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